SCHEMBL1908578

SCHEMBL1908578

C=Cc1cc(OC)cc2nc(OC)sc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
RAB9A P51151 3/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
NQO2 P16083 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP3A4 P08684 1/20 0.33
PDK1 Q15118 1/20 0.33
HPGD P15428 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
TP53 P04637 1/20 0.31
CYP2C9 P11712 1/20 0.31
APP P05067 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908612 0.84 ALDH1A1 (0.40) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL24994359 0.73 MEN1 (0.34) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL614538 0.73
SCHEMBL1908581 0.69 NPC1 (0.35) RAB9ANPC1
SCHEMBL28928501 0.66 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2NQO2CYP1A2CYP3A4
SCHEMBL9065566 0.64 CYP1A2 (0.52) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL30567454 0.64 CYP1A2 (0.52) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL24993613 0.64 ESR2 (0.35) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL11986284 0.61 ERN1 (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL13898853 0.61 CYP1A2 (0.44) ALDH1A1MEN1KMT2AKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041041-A1 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY NOVARTIS AG 2012-02-16 US disclosed
US-8076489-B2 3H-benzothiazol-2-one derivatives, for example, (R)-7-[2-(1,1-dimethyl-2-phenyl-ethylamino)-1-hydroxy-ethyl]-5-hydroxy-3H-benzothiazol-2-one; useful for treating conditions that are prevented or alleviated by activation of the beta 2-adrenoreceptor NOVARTIS AG (CH) 2011-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041041-A1 5-HYDROXY-BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY ADRB2, ADRB1, ADRA2C ALDH1A1 525/4885MEN1 3671/4885KMT2A 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.